Ays, some of which may alter the ability of EAEC to adhere to epithelial cell surfaces and other changes that may confer protection by preventing pathogen-induced cytoskeletal changes resulting in the prevention of a variety of gastrointestinal diseases. Many of the proteins identified primarily function in controlling cell structure and the cytoskeleton, transcription and translation, and cellular metabolism. It is possible that rifaximin-induced alterations to the protein expression profiles are responsible for the amelioration of some of the symptoms attributed to travelers’ diarrhea and other gastrointestinal diseases. By characterizing the protein expression profiles of cells pretreated with rifaximin different uses for rifaximin can be developed. This knowledge will also provide insight into the mechanisms by which rifaximin may protect the gut against infectious agents and how it may prevent or diminish symptoms of disease mediated unrelated to enteric pathogens as exemplified by hepatic encephalopathy, irritable bowel syndrome and inflammatory bowel disease where this drug appears to have effects.Author ContributionsConceived and designed the experiments: ELB. Performed the experiments: ELB CS MAG. Analyzed the data: ELB CS EM MAG HLD.Rifaximin Alters Epithelial Cell Protein ProfilesTable 4. Identification of Proteins.Functional Group StructuralProtein Name (Spot Number, SwissProt Accession, Average Molecular Weight in (-)-Calyculin A site Daltons) Tubulin beta chain (Spot 358 and Tentative 1315463 630, P07437, 49670.82) Tubulin alpha 1B chain (Spot 394, P68363, 50151.63) Fascin (361 and 394, Q16658, 54398.81)Transcription/TranslationalAspartyl-tRNA synthetase (394, P14868, 57136.22) Histone-binding protein RbAp48 (Spot 372, Q09028, 47524.51) Far upstream element-binding protein 1 (190, Q96AE4, 67429.19) Histone H4 (1147, P62805, 11236.15) Guanine nucleotide-binding protein subunit beta-2-like1 (768, P63244, 34945.54) 40S ribosomal protein SA (546, P08865, 32722.88) 40S ribosomal protein S7 (953, P62081, 22126.85) Heterogeneous nuclear ribonucleoprotein C1/C2 (556, P079010, 33538.81) 3-hydroxyacyl-CoA dehydrogenase type 2 (861, Q99714, 26791.89) Phenylalanyl-tRNA synthetase beta chain (212 and 216, Q9NSD9, 66115.61) Poly(rc)-binding protein 2 (565, Q15366, 38580.07) WD40 repeat-containing protein SMU1 (376, Q2TAY7, 57412.70)DNA binding Protein bindingPre-mRNA processing factor 19 (358, Q9UMS4, 55049.60) Annexin A5 (716, P08758, 35805.58) Protein NDRG1 (406, Q92597, 42835.44)Intracellular order ML240 trafficking Cytokinesis Stress response, protein foldingSyntaxin-6 (800, O435752, 29175.95) Annexin A11 Tentative (376, P50995, 54390) Tentative Heat shock protein HSP 90-alpha (190, P07900, 84528.52) Hypoxia up-regulated protein 1 (5, Q9Y4L1, 107659.97) Protein disulfide isomerase precursor (312, P07237, 55294.02)MetabolismBifunctional 39-phosphoadenosine 59-phosphosulfate synthase 1(189, O43252, 70833.15) Phosphoglycerate kinase 1 (502, P00558, 44483.49) Carbamoyl-phosphate synthase (3, P31327, 160549.19)Other doi:10.1371/journal.pone.0068550.tHaymaker (591,O96008, 37893.10)Contributed reagents/materials/analysis tools: ELB. Co-wrote the manuscript: ELB CS EM MAG HLD.
Prostate cancer is the most frequently diagnosed non-cutaneous malignancy and the third leading cause of cancer-related deaths in men in western industrialized countries [1]. The importance of androgens for the development and progression of prostate cancer was shown early in the 20th century. This resulted i.Ays, some of which may alter the ability of EAEC to adhere to epithelial cell surfaces and other changes that may confer protection by preventing pathogen-induced cytoskeletal changes resulting in the prevention of a variety of gastrointestinal diseases. Many of the proteins identified primarily function in controlling cell structure and the cytoskeleton, transcription and translation, and cellular metabolism. It is possible that rifaximin-induced alterations to the protein expression profiles are responsible for the amelioration of some of the symptoms attributed to travelers’ diarrhea and other gastrointestinal diseases. By characterizing the protein expression profiles of cells pretreated with rifaximin different uses for rifaximin can be developed. This knowledge will also provide insight into the mechanisms by which rifaximin may protect the gut against infectious agents and how it may prevent or diminish symptoms of disease mediated unrelated to enteric pathogens as exemplified by hepatic encephalopathy, irritable bowel syndrome and inflammatory bowel disease where this drug appears to have effects.Author ContributionsConceived and designed the experiments: ELB. Performed the experiments: ELB CS MAG. Analyzed the data: ELB CS EM MAG HLD.Rifaximin Alters Epithelial Cell Protein ProfilesTable 4. Identification of Proteins.Functional Group StructuralProtein Name (Spot Number, SwissProt Accession, Average Molecular Weight in Daltons) Tubulin beta chain (Spot 358 and Tentative 1315463 630, P07437, 49670.82) Tubulin alpha 1B chain (Spot 394, P68363, 50151.63) Fascin (361 and 394, Q16658, 54398.81)Transcription/TranslationalAspartyl-tRNA synthetase (394, P14868, 57136.22) Histone-binding protein RbAp48 (Spot 372, Q09028, 47524.51) Far upstream element-binding protein 1 (190, Q96AE4, 67429.19) Histone H4 (1147, P62805, 11236.15) Guanine nucleotide-binding protein subunit beta-2-like1 (768, P63244, 34945.54) 40S ribosomal protein SA (546, P08865, 32722.88) 40S ribosomal protein S7 (953, P62081, 22126.85) Heterogeneous nuclear ribonucleoprotein C1/C2 (556, P079010, 33538.81) 3-hydroxyacyl-CoA dehydrogenase type 2 (861, Q99714, 26791.89) Phenylalanyl-tRNA synthetase beta chain (212 and 216, Q9NSD9, 66115.61) Poly(rc)-binding protein 2 (565, Q15366, 38580.07) WD40 repeat-containing protein SMU1 (376, Q2TAY7, 57412.70)DNA binding Protein bindingPre-mRNA processing factor 19 (358, Q9UMS4, 55049.60) Annexin A5 (716, P08758, 35805.58) Protein NDRG1 (406, Q92597, 42835.44)Intracellular trafficking Cytokinesis Stress response, protein foldingSyntaxin-6 (800, O435752, 29175.95) Annexin A11 Tentative (376, P50995, 54390) Tentative Heat shock protein HSP 90-alpha (190, P07900, 84528.52) Hypoxia up-regulated protein 1 (5, Q9Y4L1, 107659.97) Protein disulfide isomerase precursor (312, P07237, 55294.02)MetabolismBifunctional 39-phosphoadenosine 59-phosphosulfate synthase 1(189, O43252, 70833.15) Phosphoglycerate kinase 1 (502, P00558, 44483.49) Carbamoyl-phosphate synthase (3, P31327, 160549.19)Other doi:10.1371/journal.pone.0068550.tHaymaker (591,O96008, 37893.10)Contributed reagents/materials/analysis tools: ELB. Co-wrote the manuscript: ELB CS EM MAG HLD.
Prostate cancer is the most frequently diagnosed non-cutaneous malignancy and the third leading cause of cancer-related deaths in men in western industrialized countries [1]. The importance of androgens for the development and progression of prostate cancer was shown early in the 20th century. This resulted i.
